KEYTRUDA 25 mg/mL concentrate for solution for infusion, LENVIMA 4 mg hard capsules clinical trials

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer

This study is testing a new medicine, JK08, for people with advanced cancer that can't be removed by surgery. It's looking to find the safest dose of JK08, both on its own and with other existing cancer drugs like Keytruda and Lenvima. This is one of the first times this new medicine is being given to people.